Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA
Benign prostatic hyperplasia and associated lower urinary tract symptoms (BPH/LUTS) are common conditions affecting the majority of elderly males. Here we report the results of a genome-wide association study of symptomatic BPH/LUTS in 20,621 patients and 280,541 controls of European ancestry, from...
Published in: | Nature Communications |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Text |
Language: | English |
Published: |
Nature Publishing Group UK
2018
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224563/ http://www.ncbi.nlm.nih.gov/pubmed/30410027 https://doi.org/10.1038/s41467-018-06920-9 |
Summary: | Benign prostatic hyperplasia and associated lower urinary tract symptoms (BPH/LUTS) are common conditions affecting the majority of elderly males. Here we report the results of a genome-wide association study of symptomatic BPH/LUTS in 20,621 patients and 280,541 controls of European ancestry, from Iceland and the UK. We discovered 23 genome-wide significant variants, located at 14 loci. There is little or no overlap between the BPH/LUTS variants and published prostate cancer risk variants. However, 15 of the variants reported here also associate with serum levels of prostate specific antigen (PSA) (at a Bonferroni corrected P < 0.0022). Furthermore, there is a strong genetic correlation, rg = 0.77 (P = 2.6 × 10−11), between PSA and BPH/LUTS, and one standard deviation increase in a polygenic risk score (PRS) for BPH/LUTS increases PSA levels by 12.9% (P = 1.6×10−55). These results shed a light on the genetic background of BPH/LUTS and its substantial influence on PSA levels. |
---|